Latest research on Aspart

Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. It has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Insulin aspart is produced in a genetically modified strain of _Saccharomyces cerevisiae_ and harvested from a bioreactor.

Latest findings

We, therefore, performed a randomised, parallel-group trial using continuous glucose monitoring (CGM) to assess the blood glucose fluctuations in T2DM patients, who achieved euglycemic control treated with two procedures of intensive insulin therapy, that is, MDI, Aspart 30-based MDI3 (three injections daily), and glargine based MDI4 (four injections daily). [source, 2016]
We have conducted a prospective study on a relatively large number of patients and demonstrated using CGMS that glargine based MDI4 provided better control with less blood glucose fluctuations compared to Aspart 30-based MDI3 in long-standing T2DM patients. [source, 2016]
His MDII regimen was switched from NPH and regular insulin to glargine and Aspart, with only minor reduction in hypoglycemic episodes. [source, 2016]
The patient’s daily insulin dose has been progressively increased to a regimen of glargine 115 units twice a day and Aspart 45–60 units prior to each meal. [source, 2016]
All patients were switched to insulin pump (Paradigm 712 pump, Medtronic, Northridge, CA) with rapid-acting insulin (Insulin Aspart Injection, Novo Nordisk) for 72 hours. [source, 2016]
Using an independently-generated randomization list, patients were consecutively assigned to one of two insulin regimens after enrollment: AI (insulin Aspart and insulin detemir; insulin by Novo Nordisk, Bagsvaerd, Denmark) or HI (regular insulin and NPH; insulin by Novo Nordisk, Bagsvaerd, Denmark). [source, 2016]
All patients were treated with insulin Aspart (Novo Nordisk, Bagsvaerd, Denmark) using insulin pumps (MiniMed 712E, Medtronic, Northridge, CA, USA). [source, 2016]
In total, 626 participants were randomized in a 3:1 ratio to receive once-daily insulin degludec (100 U/mL; 3 mL) or insulin glargine (100 U/mL; 3 mL), both in combination with mealtime insulin Aspart. [source, 2016]
This was an open-label, treat-to-target, non-inferiority trial comparing insulin degludec (100 U/mL) in a fixed schedule (with minimum 8 h and maximum 40 h between doses) with degludec (100 U/mL; 3 mL) or glargine (100 U/mL; 3 mL) given at the same time every day, once daily, with mealtime insulin Aspart. [source, 2016]
This trial randomized 1006 patients (3:1) to receive once-daily insulin degludec (100 U/mL; 3 mL) or glargine (100 U/mL; 3 mL), in combination with mealtime insulin Aspart, with or without prescribed Metformin, Pioglitazone or both. [source, 2016]